如果说没有头对头的试验之前，如何选择这个药，肯定是因为前面两个药，已经

If there is no head-to-head trial, how to choose this drug is definitely because the first two drugs, the drugs that have been on the market, are used on patients who are clearly not suitable for use. For example, cyclosporine is mainly kidney It is not suitable for use when there are functional problems. Tacrolimus is mainly caused by blood sugar and blood lipid problems. That is to say, when the patient already has a combination of the previous two drugs that is not suitable for the use of the previous two drugs, he can also consider using this newly marketed drug. Because there must be no such problems in this test, I see its response. By 52 weeks, the blood creatinine of its kidneys doubled, or the EGRF increased by 20% is relatively low, which means that the effect on renal function is Relatively small.

If there is no head-to-head trial before, how to choose this drug, is certainly because the first two drugs, has been marketed drugs it is used in the application of patients, clearly not suitable for use, such as cyclosporine is mainly not suitable for kidney function problems, he kemos is mainly blood sugar, blood lipids, that is to say, this patient has not been suitable for the combination of the first two drugs, can also consider the use of this new listed drug, because there is no such thing as this test. By 52 weeks, the blood creatinine in its kidneys doubled, or 20% increase in EGRF, which means that the effect on kidney function is relatively small.

If there is no head-to-head trial, how to choose this drug must be because the first two drugs, the drugs already on the market, are used in the applied patients, and the specific places are not suitable for use. For example, cyclosporine is mainly not suitable for renal function problems, and tacrolimus is mainly due to blood glucose and blood lipid problems, which means that the patient has already become unfit for use When the former two drugs are combined, we can also consider using this new drug on the market, because it is inevitable that there are no such problems in this experiment. I see its response. By the time of 52 weeks, the serum creatinine of its kidney will double or the egrf will increase by 20%, which means that the impact on renal function is relatively small.<br>